Content Delivery Network Market Analysis and Competitive Landscape Report 2025, with Akamai Technologies, Microsoft, Google, AT&T, Amazon Web Services and More
Content Delivery Network Market
Dublin, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The "Content Delivery Network Market Report 2025" has been added to ResearchAndMarkets.com's offering.The content delivery network market size has grown rapidly in recent years, from $25.8 billion in 2024 to $30.11 billion in 2025 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to internet traffic growth, globalization of internet services, mobile internet usage, user experience optimization, security concerns.The content delivery network market size is expected to see exponential growth in the next few years. It will grow to $65.65 billion in 2029 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to dynamic content personalization, quality of service improvements, interactive content delivery, content streaming standardization, global events and peak traffic handling.
Major trends in the forecast period include rise in online content consumption, security features and DDOS mitigation, multi-cloud CDN deployments, video streaming optimization, mobile content delivery optimization, application programming interface (API) protection, global expansion of CDN networks.
The increase in usage of the internet and smart devices is expected to propel the growth of the content delivery network market. The number of smartphone users has increased significantly over the world due to its ease and the services offered. These services provide door-to-door services to their users which makes them convenient for use. Smartphones have access to the internet that provides a better outlook on the various social media applications where content is generated and uploaded every second. According to Bankmycell, a buyback mobile store in the USA, in 2022, the number of smartphones users are 6. 648 billion globally is 83. 89 % of the population. Moreover, there are 7. 92 billion mobile connections in the world. It is predicted that by 2025, 72 % of all internet users will access the internet only through their smartphones. Such rising usage of the internet and smart devices is expected to drive the content delivery network market growth.The increased number of connected television (TVs) is expected to drive the growth of content delivery network market. Connected TVs, also known as smart TVs, refer to television sets equipped with internet connectivity and the ability to access online content and services. Connected TVs use content delivery network for better streaming services, OTT content, interactive advertisement, and enhanced live streaming. For instance, in April 2023 according to Eskimi, a Lithuania-based advertising services provider, in 2022, the count of monthly connected TV users within the Millennial demographic stood at 60. 5 million, and it is projected to increase to 62. 6 million by 2025, reflecting a growth of 2. 1 million. Furthermore, 87% of US TV households possess at least one Internet-connected TV device, encompassing smart TVs, standalone streaming devices, connected video game systems, or connected Blu-ray players. Therefore, the increased number of connected TVs is expected to propel the growth of content delivery network market going forward.Major companies in the content delivery network market are focused on developing advanced technologies, such as M-Files Smart Migration, to better serve customers with enhanced features. This solution optimizes data transfer and ensures smooth integration during platform upgrades, consolidations, or cloud transitions, reducing downtime and maintaining data integrity. For example, in January 2022, M-Files Corporation, a US-based provider of content services platforms, launched M-Files Smart Migration. This intelligent service combines M-Files' advanced information management capabilities with metadata-driven automation, aiming to assist customers in migrating their information onto the M-Files platform more intelligently and cost-effectively. A standout feature of smart migration is its seamless and systematic process for migrating documents from external repositories to M-Files. This allows customers to easily classify and enhance the migrated content with metadata. The tool emphasizes meaningful content, facilitates immediate insights from migrated data, and empowers organizations to improve efficiencies and drive business growth.Major companies operating in the content delivery network market include Akamai Technologies, Microsoft, Google,AT&T Inc., Amazon Web Services Inc., Limelight Networks, Fastly Inc., Cloudflare Inc.,Verizon Communications Inc., IBM, Tata Communications Ltd., OnApp Limited,Quantil Inc., Alibaba. com, CenturyLink Technology Singapore Pte. Ltd, Lumen Technologies, StackPath LLC., Deutsche Telekom AG, G-Core Labs S. A, Rackspace Technology, Tencent Cloud, iScaler Ltd., Imperva Inc., CDNetworks Co. Ltd., Sucuri Inc., Leaseweb and Internap Holding.This report focuses on content delivery network market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Markets Covered:
By Content Type: Static Content; Dynamic Content
By Component: Solution; Services
By Provider Type: Traditional CDN; Cloud CDN; P2P CDN; Telecom CDN
By End-User: Media And Entertainment; Advertising; E-Commerce; Healthcare; Business And Financial Services; Research And Education; Other End-users
Subsegments:
By Static Content: Images; Videos; HTML Or CSS Or JavaScript Files; Software Downloads
By Dynamic Content: Web Applications; API Responses; Personalized Content; Real-Time Data Feeds
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2025 - 2029
Estimated Market Value (USD) in 2025
$30.11 Billion
Forecasted Market Value (USD) by 2029
$65.65 Billion
Compound Annual Growth Rate
21.5%
Regions Covered
Global
Key Topics Covered: 1. Executive Summary2. Content Delivery Network Market Characteristics3. Content Delivery Network Market Trends And Strategies4. Content Delivery Network Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market5. Global Content Delivery Network Growth Analysis And Strategic Analysis Framework5.1. Global Content Delivery Network PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)5.2. Analysis Of End Use Industries5.3. Global Content Delivery Network Market Growth Rate Analysis5.4. Global Content Delivery Network Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)5.5. Global Content Delivery Network Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)5.6. Global Content Delivery Network Total Addressable Market (TAM)6. Content Delivery Network Market Segmentation6.1. Global Content Delivery Network Market, Segmentation By Content Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Static Content
Dynamic Content
6.2. Global Content Delivery Network Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solution
Services
6.3. Global Content Delivery Network Market, Segmentation By Provider Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Traditional CDN
Cloud CDN
P2P CDN
Telecom CDN
6.4. Global Content Delivery Network Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Media And Entertainment
Advertising
E-Commerce
Healthcare
Business And Financial Services
Research And Education
Other End-users
6.5. Global Content Delivery Network Market, Sub-Segmentation Of Static Content, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Images
Videos
HTML Or CSS Or JavaScript Files
Software Downloads
6.6. Global Content Delivery Network Market, Sub-Segmentation Of Dynamic Content, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Web Applications
API Responses
Personalized Content
Real-Time Data Feeds
7. Content Delivery Network Market Regional And Country Analysis7.1. Global Content Delivery Network Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion7.2. Global Content Delivery Network Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion8-29. Country Specific Asia-Pacific Content Delivery Network Analysis30. Content Delivery Network Market Competitive Landscape And Company Profiles30.1. Content Delivery Network Market Competitive Landscape30.2. Content Delivery Network Market Company Profiles
Akamai Technologies
Microsoft
Google
AT&T
Amazon Web Services
31. Content Delivery Network Market Other Major And Innovative Companies
Limelight Networks
Fastly Inc.
Cloudflare Inc.
Verizon Communications Inc.
IBM
Tata Communications Ltd.
OnApp Limited
Quantil Inc.
Alibaba. com
CenturyLink Technology Singapore Pte. Ltd
Lumen Technologies
StackPath
Deutsche Telekom
G-Core Labs S. A
Rackspace Technology
32. Global Content Delivery Network Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Content Delivery Network Market34. Recent Developments In The Content Delivery Network Market35. Content Delivery Network Market High Potential Countries, Segments and StrategiesFor more information about this report visit https://www.researchandmarkets.com/r/dpar9b
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Content Delivery Network Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Making private assets accessible to your 401(k): Expert weighs in
Empower announced that it will be offering private market investments and real estate opportunities for clients' 401(k) plans. Bow River Capital managing director of evergreen strategies Jeremy Held sits down with Wealth's Brad Smith to speak more about these trends and the illiquid nature of these asset classes. Hear more about three types of alternate assets to consider adding to your personal portfolio. To watch more expert insights and analysis on the latest market action, check out more Wealth here. Wall Street is increasingly interested in bringing private assets to everyday investors. Financial services firm Empower, which oversees $1.8 trillion in 401k accounts for 19 million people, recently announced that it will offer private credit, equity, and real estate into some of its accounts later on this year. But there are certain issues tied to private assets and mainstream use. According to our very own Bob Powell, private assets can be complex and illiquid, meaning they aren't. Easily bought or sold, these assets tend to have higher fees and there's less transparency because private companies aren't subject to the same disclosure rules as public companies. Our next guest says that there's plumbing that will have to be modified to allow these assets into 401ks. Here with more we've got Jeremy Held who is the managing director of Evergreen Strategies at Boat River Capital. Great to have you here with us. Boat River we know is a Denver-based. Alternative asset managers specializing in private credit equity and real estate among other assets. So what kind of changes do need to be made to that plumbing in order for this to be reality and accessible to more people saving for retirement? Yeah, look, I think the 401k market is a huge opportunity for investors to access the same types of private investments that institutional investors have had for years. The problem is and the challenges, and these are challenges that can be overcome. Is that the plumbing, the operations, the mechanics of investing in 401ks is really made for mutual funds with daily accessibility, and I do think that the benefits do outweigh some of those challenges in terms of accessing just a much broader set of investments so I do think that. The 401k industry, the private equity industry, the, the operations firms that access the space will definitely make changes because I think it's in the, in the best interest of investors to have access to private companies in addition to public companies. And so we had talked about the liquid nature of some of these investments if they were packaged up and put into a broader investment vehicle for retirement. Should people who are saving for retirement still be concerned about the illiquid nature or what should be the thought process or the conversations you're having? Yeah, you know it's, it's a great question. I think you know what investors should be asking themselves at all times, whether they're retirement investors, taxable investors, is do I need to have 100% of my assets, 100% liquid, 100% of the time. And if the answer to that is no, even if it's 85% or 90 or 95% of their assets are liquid, if they open up a small percentage to being illiquid, you can really open up the opportunity set for investors and and invest in a much broader array of companies. And so with that in mind, what is kind of the time horizon that you see more often among the clients that you're working with? Yeah, I mean, typically. We're working with long term oriented clients. They're they're building a financial plan for 5 years, 10 years, 20 years and beyond. I mean you think about it, 401k accounts are really ideally suited for a long investment horizon. You have people that are contributing to their 401k accounts in their 20s and 30s. They have a long term time horizon, and I think private assets are really ideally suited for that time horizon for some of those private assets. I, I wonder what happens and how do you approach it when a private company. Makes their foray into becoming a publicly traded company because obviously the liquidity profile then changes significantly. It does and I think what's happened a lot over the past really two or three decades, there's half as many public companies today as there were in the 90s. Companies are staying private a lot longer. A lot of private, a lot of public companies are being taken. And so there is that that opportunity for a private company to go public, but there's also the opportunity for public companies to go private, and I think investors want to have access to that broader that broader universe. What are the other assets outside of companies as we talk about and think about real estate and the credit side of this too? Yeah, I think when people think about accessing markets today. They're not just thinking about public or private, they're saying I want an allocation to real estate and I'm gonna own some public real estate and some private real estate. I want an allocation to credit. I'll own some public credit and some private credit and the same thing, of course, in in equity. I'm gonna own public equities and private equity. And they think about how do I build the most diversified portfolio possible and that includes both public and private assets. What's the entry point for a retirement vehicle like this? Yeah, I think Evergreen funds, which are a new type of vehicle that are really transforming the way people access private investments, is really the best entry point. These are vehicles that are immediately invested. They're highly diversified minimums as low as $50,000 and that's really a much more efficient way for a broader universe like 401k investors to access the private markets. Do you see those minimums going lower in the future as more people try to gain exposure? I do. I do think there's gonna be some changes from a regulatory perspective. Historically, alternative investments have been limited to qualified purchasers, accredited investors. Those eliminations, those restrictions are going away, and I do think you'll see minimums go from what used to be 5 million now it went to $1,050,000 and ultimately those will go even below there. Great to have you here with us, Jeremy in town from Denver, Colorado. Appreciate the time. Yeah, thanks, Brad.
Yahoo
35 minutes ago
- Yahoo
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from the 180mg cohort of the Company's SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported in the 180mg cohort. 'We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'In addition to the responses observed, we are pleased that briquilimab continued to be well tolerated in the study. Taken together with the results observed thus far in the BEACON study in CSU, these data demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms, along with a potentially differentiated safety profile. On behalf of the entire Jasper team, I'd like to thank both the investigators and the patients who participated in SPOTLIGHT, along with their families and caregivers.' SPOTLIGHT Study Design and Data Summary: The SPOTLIGHT study is a Phase 1b/2a open label clinical trial evaluating a single dose of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD), the two most prevalent sub types of CIndU, who are refractory to antihistamines. The study enrolled 27 participants across three dose cohorts, 40mg (n=3), 120mg (n=12), and 180mg (n=12). The primary endpoints are safety and tolerability of briquilimab and secondary endpoints are focused on clinical activity and PK/PD, including measurement of serum tryptase. Among the 12 participants enrolled in the 180mg cohort, 3 were diagnosed with ColdU (25%) and 9 with SD (75%). Participants had high disease burden as assessed by provocation threshold testing. In the 180mg cohort, mean baseline TempTest® threshold was 18.7°C (range: 10-26°C) for ColdU participants, and mean baseline FricTest® threshold was 3.7 of 4 (range: 3-4) for SD participants. 12 of 12 participants (100%) enrolled in the 180mg dose cohort achieved a clinical response to provocation testing within the 8-week preliminary analysis period following treatment. 11 of 12 participants (92%) treated in the cohort achieved a complete response (CR) with either their critical temperature threshold improving to at least 4°C for ColdU participants or their FricTest® score improving to 0 for SD participants, and 1 of 12 participants achieved a partial response (PR) as their best response. Complete responses in TempTest® or FricTest® were observed as early as 1 week following dosing in the 180mg cohort, with 8 of 12 participants (66%) achieving CR or PR by week 2. Overall, 22 of 27 participants (81%) enrolled in the study achieved a CR and 26 of 27 participants (96%) achieved a CR or PR. Briquilimab40mg(n=3) Briquilimab120mg(n=12) Briquilimab180mg(n=12) BriquilimabAll doses (n=27) Complete Response, n (%) 1 (33.3%) 10 (83.3%) 11 (91.6%) 22 (81.5%) ColdU, n 0 3 3 6 Symptomatic Dermographism, n 1 7 8 16 Partial Response, n (%) 2 (66.7%) 1 (8.3%) 1 (8.4%) 4 (14.8%) ColdU, n 1 0 0 1 Symptomatic Dermographism, n 1 1 1 3 Complete or Partial Response at any time, n (%) 3 (100%) 11 (91.6%) 12 (100%) 26 (96.3%) At the 8-week timepoint following treatment, 7 of 12 (58%) participants in the 180mg cohort maintained an ongoing clinical response, with 5 participants achieving CR and 2 participants achieving PR. Mean baseline serum tryptase for participants in the 180mg cohort was 5.1 ng/ml (standard deviation: 2.29 ng/ml). Significant reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase measurements below the lower limit of quantification were observed in 10 of 12 participants (83%) in the 180mg cohort. Briquilimab was well tolerated in the study. No SAEs or AEs ≥ grade 3 were reported in the 180mg cohort. Furthermore, there were no reported AEs related to hair or skin color changes. 2 of 12 participants (17%) enrolled in the 180mg cohort experienced taste change/hypogeusia. Mild, transient drops in neutrophil counts were observed, with 6 of 12 participants (50%) experiencing grade 1 or grade 2 neutrophil count decreases which resolved in a median of 16 days. 5 of the 6 participants who experienced neutrophil count decreases were diagnosed with concurrent viral infections that may have contributed to observed decreases. 'It is exciting to see additional clinical data showing that treatment with briquilimab can lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population,' said Martin Metz, M.D., Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin. 'Notably, the safety and tolerability results observed in both the SPOTLIGHT and BEACON studies thus far show that the adverse events possibly caused by briquilimab are mostly low frequency, low grade, and resolve quickly. Patients with CIndU currently have very few treatment options, and I look forward to continuing to support the development of novel therapeutics to treat this debilitating disease.' Conference Call / Webinar Jasper will host a conference call and webinar on Monday, June 16, 2025, at 8:00 a.m. EDT. A live question and answer session with management will follow the formal presentations. A link to the webinar, including presentation slides, can be found here. To access the live conference call via phone, dial 1-844-826-3033 from the US or 1-412-317-5185 from outside the US, or click here. The conference ID is 10200147, and the conference call passcode is 6392607. The presentation slides and a link to the live and archived webinar will also be available on the Events & News – Events page of Jasper's Investor Relations website. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; briquilimab's ability to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms along with a potentially differentiated safety profile; and the potential for treatment with briquilimab to lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Lauren Walker (media) Real Chemistry 646-564-2156 lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
WestJet dealing with 'cybersecurity incident' impacting access to internal systems, app
WestJet is alerting its employees and the public about a "cybersecurity incident" involving the Calgary-based airline's internal systems and app. In a news release on Friday, the airline said several people trying to access its services have faced "restricted access" as a result of the incident. "We have activated specialized internal teams in co-operation with law enforcement and Transport Canada to investigate the matter and limit impacts." The release said the airline is "expediting efforts" to keep its operations safe and "safeguard sensitive data and personal information," and apologizes for any disruption to access to its services. It added it's "too early to speculate on any details," but WestJet will share more information when available, and advises people using its services and employees to be cautious about sharing personal data. CBC News reached out on Saturday morning to WestJet to get clarification on information in its release and for more details, including how many people may have been impacted and whether anyone's personal information has been accessed. This story will be updated with any response.
